Who are Anthrax Immune Globulin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): RSV Polyclonal Immunoglobulin, human histaglobulin, IgY.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anthrax-immune-globulin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Anthrax Immune Globulin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anthrax Immune Globulin (Anthrax Immune Globulin) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Polyclonal immunoglobulin; passive immunotherapy. Area: Infectious Disease; Immunology.

marketed Polyclonal immunoglobulin; passive immunotherapy Anthrax protective antigen (PA); anthrax lethal factor (LF) Infectious Disease; Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Anthrax Immune Globulin (Anthrax Immune Globulin) — National Institutes of Health Clinical Center (CC). Anthrax Immune Globulin provides passive immunization by supplying antibodies that neutralize anthrax toxins and enhance clearance of Bacillus anthracis.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Anthrax Immune Globulin TARGET	Anthrax Immune Globulin	National Institutes of Health Clinical Center (CC)	marketed	Polyclonal immunoglobulin; passive immunotherapy	Anthrax protective antigen (PA); anthrax lethal factor (LF)
RSV Polyclonal Immunoglobulin	RSV Polyclonal Immunoglobulin	National Institute of Allergy and Infectious Diseases (NIAID)	marketed	Polyclonal immunoglobulin	Respiratory syncytial virus (RSV) surface proteins
human histaglobulin	human histaglobulin	Hangzhou Grand Biologic Pharmaceutical, Inc.	marketed	Polyclonal immunoglobulin; antihistamine immunoglobulin	Histamine and mast cell stabilization
IgY	IgY	Mukoviszidose Institut gGmbH	phase 3	Polyclonal immunoglobulin Y (IgY) therapeutic	Pseudomonas aeruginosa lipopolysaccharide and surface antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Polyclonal immunoglobulin; passive immunotherapy class)

National Institutes of Health Clinical Center (CC) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anthrax Immune Globulin — Competitive Intelligence Brief. https://druglandscape.com/ci/anthrax-immune-globulin. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing